// App-Quantinova.ai

7525 : Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.

Researchers

Presenter

  • Graeme Fraser

Principal Investigators

  • Fatih Demirkan

  • Rodrigo Santucci Silva

  • Halyna Pylypenko

  • Sebastian Grosicki

  • Ann Janssens

  • Aleksander Pristupa

  • Jiri Mayer

  • Marie-Sarah Dilhuydy

  • Javier Loscertales

  • Andre Goy

  • Abraham Avigdor

  • Simon Rule

  • Charles Phelps

  • Michelle Mahler

  • Mariya Salman

  • Angela J. Howes

  • Sriram Balasubramanian

  • Asher Alban Akmal Chanan-Khan

Medical Centers

  • Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada

  • Department I of Internal Medicine and German CLL Study Group, University of Cologne, Cologne, Germany

  • Division of Hematology, Dokuz Eylul University, Izmir, Turkey

  • IEP Sao Lucas / Hemomed Oncologia e Hematologia, Sao Paulo, Brazil

  • Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine

  • Hematology Department, Community of Hospitals, Chorzow, Poland

  • Universitaire Ziekenhuizen Leuven, Leuven, Belgium

  • Regional Clinical Hospital, Ryazan, Russia

  • University Hospital Brno, Brno, Czech Republic

  • Hopital Haut Leveque, Bordeaux, France

  • Hematology Department, Hospital Universitario La Princesa, Madrid, Spain

  • John Theurer Cancer Centre, Hackensack University Medical Center, Hackensack, NJ

  • Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer and Sackler School of Medicine,University of Tel-Aviv, Tel-Aviv, Israel

  • Department of Haematology, Derriford Hospital, Plymouth, United Kingdom

  • Janssen Research & Development, LLC, Raritan, NJ

  • Janssen Research & Development, High Wycombe, United Kingdom

  • Janssen Research and Development, LLC, Spring House, PA

  • Mayo Clinic, Jacksonville, FL

Locations

  • Brazil

  • Canada

  • Czech Republic

  • Poland

  • Germany

  • Turkey

  • Spain

  • United Kingdom

  • United States

  • Ukraine

  • France

  • Russia

  • Belgium

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Bendamustine

  • Ibrutinib

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01611090

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved